Twist Bioscience Corp. (TWST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$125.52-1.98%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Twist Bioscience raised revenue guidance to $442-$447 million for FY26. Revenue grew from $84.7M in 2024-Q4 to $110.7M in 2026-Q2. Management aims to break even on adjusted EBITDA by Q4 FY26. Gross margin is expected above 52% for FY26.
The company is still loss-making with negative free cash flow. Adjusted EBITDA breakeven is behind schedule. Revenue growth may slow or miss raised guidance. Profit margins could stay under pressure.
The price is about 15% above our fair value near $79. Analysts expect 21% revenue growth. Our fair value is below the Street median of $87.
Breaks if: Adjusted EBITDA remains negative after Q4 FY26
Management aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation, as TWST aims to achieve adjusted EBITDA breakeven while navigating a tough environment. The current thesis state is cautious, reflecting recent earnings misses and mixed management execution.
The market seems to have priced in a justified valuation, with a low expectations gap. However, TWST trades at a premium compared to peers, suggesting that investors may expect a turnaround in performance.
Management is focused on achieving breakeven and driving revenue growth, which has shown some positive momentum. However, the company's recent financial performance has been weak, and risks remain elevated in the near term.
The thesis hinges on management's ability to meet guidance and improve financial performance. Additionally, broader sector trends and economic conditions, such as job reports, will play a critical role in shaping TWST's outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company raised its FY26 revenue guidance to $456-$457 million. This supports a positive outlook for revenue growth. However, the latest earnings report showed a miss, which raises concerns.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Gross margin falls below 50% in FY26
Breaks if: Revenue falls below $442 million in FY26
In the next 1 to 3 years, TWST's performance will depend on its execution against targets and external economic factors. Not investment advice.